Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 9/20 | 0.68 |
| ▸ | HSD17B2 | P37059 | 9/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 3/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | IDH1 | O75874 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13006310 | 0.86 | HSD17B1 (0.58) | HSD17B1HSD17B2CYP3A4CYP2C9CYP17A1 | |
| SCHEMBL11326904 | 0.85 | BCL2 (0.53) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL27559833 | 0.85 | HSD17B1 (0.63) | HSD17B1HSD17B2CYP3A4CYP2C9CYP17A1 | |
| Propane SCHEMBL28420780 | 0.83 | HSD17B1 (0.83) | HSD17B1HSD17B2CYP3A4CYP2C9CYP17A1 | |
| SCHEMBL27704396 | 0.83 | ESR1 (0.60) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL18924172 | 0.83 | DRD2 (0.52) | — | |
| Propane SCHEMBL5843489 | 0.83 | HSD17B1 (0.71) | HSD17B1HSD17B2CYP3A4CYP2C9CYP17A1 | |
| SCHEMBL7898375 | 0.82 | HSD17B1 (1.00) | HSD17B1HSD17B2CYP3A4CYP2C9CYP17A1 | |
| SCHEMBL29924029 | 0.81 | BCL2 (0.65) | CYP1A2BCL2 | |
| SCHEMBL9007144 | 0.81 | BCL2 (0.65) | CYP1A2BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925755-B1 | NEUROPROTECTIVE AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV WAYNE STATE (US) | 2021-09-08 | — | — | EP | disclosed |
| WO-2021119249-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| EP-2604269-B1 | 1,4-benzodiazepine-2,5-diones with therapeutic properties | UNIV MICHIGAN (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8791104-B2 | 1,4-benzodiazepine-2,5-diones with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130261110-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2604269-A1 | 1,4-benzodiazepine-2,5-diones with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-06-19 | — | — | EP | disclosed |
| EP-1948191-B1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | UNIV MICHIGAN (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2008116156-A2 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS ASSOCIATED WITH MITOCHONDRIAL FUNCTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2007053193-A2 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053725-A2 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261110-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | BAD, GABRA5, GABRB1 | HSD17B1 469/4885HSD17B2 462/4885CYP3A4 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.